Showing posts sorted by date for query zoonotic. Sort by relevance Show all posts
Showing posts sorted by date for query zoonotic. Sort by relevance Show all posts

Thursday, October 08, 2026

 

1 in 20 pet cats in North America might have Giardia infection, with young, male, unneutered cats especially at risk, per analysis of more than 150,000 feline stool samples



PLOS
Giardia duodenalis in domestic cats from the US and Canada: Prevalence and zoonotic potential

image: 

Map of Giardia duodenalis detected in cats from United States.

view more 

Credit: Wingerd et al., 2026, PLOS One, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)





1 in 20 pet cats in North America might have Giardia infection, with young, male, unneutered cats especially at risk, per analysis of more than 150,000 feline stool samples

Article URL: https://plos.io/4hjS21j

Article title: Giardia duodenalis in domestic cats from the US and Canada: Prevalence and zoonotic potential

Author countries: USA, Colombia.

Funding: The author(s) received no specific funding for this work.

Tuesday, October 06, 2026

Black Death hits Russia. It never really went away.

A case of plague was reported in Russia this week. An outbreak is unlikely, but the Black Death, which was born in Central Asia, never really went away. 
Black Death hits Russia. It never really went away.
By Ben Aris in Berlin October 5, 2026

Russia has quarantined and tested nearly 200 people following the mysterious death of a scientist at a Siberian anti-plague institute, triggering panic reporting that the Black Death has reappeared in Russia. The EU says it is “monitoring the situation very closely” and there have been calls to close the borders in case the illness spreads.

And the danger is real as the bubonic plague spores are still active in many of the former Soviet republics and there is usually an infection reported every year. Mongolia is particularly prone to outbreaks as locals hunt marmots, which are considered a delicacy, and have taken over from rats as the main carrier of the infection in modern times.

However, there is a great deal of confusion over what happened. Moscow has insisted that the victim, a labour worker at a medical institution, died from an unidentified form of pneumonia and there is no cause for alarm. But no one really trusts Moscow, especially when it comes to natural disasters. The Soviet government didn’t report the meltdown at Chernobyl for over 36 hours and hid the scale of the disaster from the public in 1986 and not much has changed since then.

Alarm bells began to ring after Darya Shipilova, a 28-year-old employee of the Irkutsk Anti-Plague Research Institute of Siberia and the Far East, was admitted to hospital in Shelekhov, near Irkutsk, with severe pneumonia in a just over a week ago and died days later.

Early reports claimed Shipilova had accidentally broken a test tube containing live plague bacteria while collecting samples. Russia keeps a number of deadly pathogens like Anthrax in storage in its medical institutes for research purposes, although it has signed off on the Chemical Weapons Convention (CWC) in 1993 and ratified it in 1997 that preclude their use by the military and has committed to destroy what remaining stockpiles of biohazardous agents it still had soon after.

Local media described the suspected infection as pneumonic plague, the most dangerous form of the disease because it attacks the lungs and, unlike the more familiar bubonic form, can spread directly between people through respiratory particles.

The reports triggered a rapid response. At least 197 people who had been in contact with Shipilova were placed under medical observation, including 189 who were hospitalised. Of those, 114 were reportedly held in one regional hospital, 63 in another and 12 at the anti-plague institute.

“All identified contact persons have been placed under medical observation. As of today, the contacts show no signs of illness, and their laboratory test results are negative,” Irkutsk Governor Igor Kobzev said. Typically, the illness has a 4-7 days incubation period before the first symptoms is detectable. It is extremely lethal if not immediately treated with antibiotics, killing 98% of its victims between 18-24 hours. However, it is not particularly infectious, spreading mainly through large respiratory droplets during close contact, with a low R0 rate of only 1.2-1.3 (one infected person typically infects one more person on average.)

The Shelekhov district hospital imposed quarantine restrictions, public events were postponed and Russia’s chief state sanitary doctor Anna Popova travelled to the region to oversee the response.

The nearby Irkutsk Aluminium Smelter, operated by Rusal (HKEX: 486; MOEX: RUAL), introduced mandatory masks for its 2,154 employees.

“We have introduced a mask protocol at the facility as a precaution. God protects the cautious, so follow safety measures. If symptoms appear, seek medical help immediately,” plant director Artyom Fominykh said.

But the official story then changed.

Russia’s consumer health watchdog Rospotrebnadzor said Shipilova did not die of plague and diagnosed her instead with “pneumonia of unknown aetiology”. Tests found no microorganisms associated with the dangerous pathogens she handled at work, according to the agency, while an investigation found no evidence that a laboratory accident had occurred.

Officials said subsequent testing of Shipilova’s contacts had found two cases of Covid-19 and two rhinovirus infections, but no plague.

Gennady Onishchenko, an epidemiologist and former head of Rospotrebnadzor, said the illness was “likely not plague”, while stressing that Russia had established treatment and prevention procedures should plague be confirmed.

Occasional outbreaks

Nevertheless, the scale of the precautions — quarantines, medical surveillance, masks and the personal intervention of Popova — has attracted attention as the former Soviet Union space does see occasional outbreaks of the bubonic plague, which killed a between a third and half of Europe’s population when it first appeared in the 14th century.

WHO has identified active natural plague foci across Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan, covering about 1.8mn square kilometres, with sporadic cases historically registered almost every year in the region.

The European Commission said it was monitoring the situation “very closely” and was in contact with the European Centre for Disease Prevention and Control.

“We are aware of the reports concerning the laboratory incident in Russia, seemingly involving a pathogen causing plague,” a Commission spokesperson said.

“Public health is always a priority for us, so we are in touch with our experts from the European Centre for Disease Prevention and Control,” the spokesperson added but saying it was not in contact with Russian officials since Russia's full-scale invasion of Ukraine.

“We are much better prepared for any pandemics” following the coronavirus crisis, the spokesperson said, during which significant antibiotic stocks were built up.

Washington is also monitoring events. US officials have urged Moscow to provide “accurate” information “quickly and openly”, while Brussels has called for “timely and transparent reporting”.

But for the moment there is no confirmed plague outbreak. No secondary plague cases have been reported and Russia says laboratory analysis does not support the theory that Shipilova contracted Yersinia pestis.

The Black Death never disappeared

Plague is caused by Yersinia pestis, a bacterium that survives naturally in populations of wild rodents and the fleas that live on them.

The disease still exists across parts of Asia, Africa and the Americas. Most recent cases reported to the WHO have been in the Democratic Republic of Congo and Madagascar, but natural plague reservoirs also persist across parts of Central Asia and Siberia.

Modern medicine has also radically changed the danger posed by the disease. When it first appeared, arriving on rats travelling with merchants along the Silk Road from Central Asia and merchant ships trading with Asia, it cut through Europe’s unprotected populations like a hot knife through butter. But since then the plague can be treated effectively with antibiotics if diagnosed quickly.

WHO says untreated bubonic plague has a fatality rate of roughly 30-60%, while untreated pneumonic and septicaemic plague are effectively invariably fatal. Pneumonic plague can kill within 18-24 hours of the onset of symptoms if treatment is not started, but recovery rates are high when antibiotics are administered early.

Over the years, Russia itself has recorded sporadic human infections. The last confirmed Russian case was in 2016, when a 10-year-old boy in the Altai Republic contracted bubonic plague after helping his grandfather skin a marmot. The boy reportedly cut himself while handling the animal. Seventeen contacts, including six children, were quarantined, and the boy survived after treatment.

Russian scientific literature records human cases in the same high-altitude Altai plague focus in 2014, 2015 and 2016, all associated with handling grey marmot carcasses.

But it is Mongolia which is most prone to infections and death. Marmots — large ground-dwelling rodents similar to ferrets — are a principal natural host for plague in Mongolia.

Mongolia's National Centre for Zoonotic Diseases says natural plague foci have been identified across 28.3% of the country's territory, covering 132 soums in 18 provinces. More than half of the roughly 3,000 plague strains isolated in Mongolia since 1928 have come from Mongolian marmots, while another 27% were isolated from ectoparasites including marmot fleas.

That creates a particular problem because hunting and eating marmots remains a tradition in parts of the country despite restrictions and the locals are so keen on the meat that they routinely ignore government warnings and continue to trap the rodents.

Research into Mongolian plague cases found 73 reported human infections between 1998 and 2020, of which 59% were associated with close contact with infected marmots and 7% with eating raw marmot organs.

In July 2020, two brothers aged 27 and 16 in western Mongolia's Khovd province contracted bubonic plague after hunting and eating marmot. Authorities quarantined their contacts and restricted travel while the pair were treated, who survived.

Later that month, a 15-year-old boy died in Govi-Altai province after contracting plague following the hunting and consumption of a marmot. Fifteen people who had been in contact with him were isolated and given antibiotic treatment.

A year earlier, two people died again after consuming raw marmot organs in Mongolia.

Marmot hunting has been banned, but enforcement is difficult and the animals remain a prized food in some rural communities. Parts of the animal are also traditionally believed to possess health-giving properties.

In Mongolia the disease is often referred to colloquially as the “Marmot Plague”, a name that obscures the fact that it is caused by exactly the same bacterium associated with history's most notorious pandemic.

The connection between Central Asia and plague goes much deeper than today's occasional outbreaks.

A landmark genetic study published in Nature in 2022 traced the probable source of the plague strain behind the 14th-century Black Death to the Tian Shan region around modern Kyrgyzstan.

Researchers examined human remains from the Kara-Djigach and Burana cemeteries near Lake Issyk-Kul, the smaller sister lake to Baikal in Siberia, where an unusually large number of tombstones dating from 1338 and 1339 explicitly referred to deaths from “pestilence”.

Ancient DNA recovered from seven individuals revealed Yersinia pestis in three of them. Researchers reconstructed two plague genomes which they identified as ancestors of the enormous diversification of plague strains associated with the Black Death that swept through western Eurasia beginning several years later.

“It is like finding the place where all the strains come together, like with coronavirus where we have Alpha, Delta, Omicron all coming from this strain in Wuhan, [China],” Johannes Krause, a palaeogeneticist at the Max Planck Institute for Evolutionary Anthropology in Leipzig and one of the study's leaders, said at the time. “It was like a big bang of plague,” Krause said.


Saturday, October 03, 2026

 

LSTM announces new £4.5 million partnership to tackle neglected tropical diseases



Liverpool School of Tropical Medicine
A patient with lymphatic filariasis

image: 

A patient with lymphatic filariasis

view more 

Credit: Liverpool School of Tropical Medicine



 

Liverpool School of Tropical Medicine (LSTM) has announced a new partnership to develop innovative, acceptable and feasible tools to accelerate progress towards eliminating two neglected tropical diseases (NTDs).

 

ENDPOINT (rEsearch aNd DeveloPment fOr elimInation of NTds) is a major UK aid-funded initiative coordinated by LSTM’s Centre for Drugs and Diagnostics and Centre for Neglected Tropical Diseases, working with the LSTM-led Infection Innovation Consortium (iiCON) and The Leprosy Mission in Nepal, University of Buea, Cameroon and University of Bonn in Germany.

 

The programme focuses on the filarial parasitic infections lymphatic filariasis and onchocerciasis. Together these debilitating diseases affect an estimated 78 million people, with a further one billion at risk, causing major health problems and significantly undermining economic prosperity in endemic communities.

 

As a cross-disciplinary product development partnership (PDP), ENDPOINT will advance a pipeline of innovative diagnostic and treatment tools, while generating evidence on their acceptability and feasibility within affected communities and health systems, as well as potential policy and regulatory pathways.

 

The £4.5m project is funded by UK aid through the UK Government’s Foreign, Commonwealth and Development Office (FCDO) as part of the Global Research and Technology Development fund, launched earlier this year, which supports PDPs like ENDPOINT to tackle global challenges like neglected tropical diseases.

 

Professor Joseph Turner, co-director of the Centre for Drugs and Diagnostics and research director of the PDP, said: “We are immensely grateful for this valuable FCDO investment in our CDD iiCON filarial NTDs product development portfolio.

 

“With our partners in Nepal and Cameroon, our pipeline of innovative diagnostic and therapeutic candidates have been selected to overcome specific barriers to lymphatic filariasis and onchocerciasis elimination.

 

“We will evaluate candidate product effectiveness and acceptability by affected communities in order to refine and accelerate their onward development.”

 

ENDPOINT brings together a portfolio of complementary projects:

  • a wearable microwave biosensor diagnostic to support non-invasive detection and surveillance of lymphatic filariasis in Nepal;
  • repurposing the oral antibiotic fusidic acid as a shorter-course treatment for onchocerciasis (the second leading infectious cause of blindness worldwide), complementing the LSTM-led FAME study;
  • early development of a new class of fast-acting anti-Wolbachia drug candidates in the UK, with the potential to treat or prevent onchocerciasis, lymphatic filariasis and veterinary zoonotic filariasis.

 

Dr Rachael Thomson, Endpoint CEO, said: “To receive this funding is a real achievement for ENDPOINT and LSTM. This investment strengthens the global research pipeline for NTDs and reinforces our commitment to delivering equitable, impactful solutions for affected communities.”

 

By combining cutting-edge technologies with strong in-country partnerships, ENDPOINT aims to generate high-quality evidence, support and de-risk the development of scalable solutions that are acceptable to communities and health systems, and strengthen national research and development capacity in endemic countries.

 

FAME is a complementary clinical trial funded by a £4.9 million award from the European and Developing Countries Clinical Trials Partnership (EDCTP3), with additional support from the Drugs for Neglected Diseases initiative (DNDi).

The study is generating critical evidence on the potential of repurposing the antibiotic fusidic acid to treat onchocerciasis and support the future uptake of antibiotic-based tools for filarial disease elimination.

Together, ENDPOINT and FAME represent nearly £9.4 million in new investment reaffirming LSTMs long-standing leadership in research and development to progress filarial NTD elimination.

Find out more about research and innovation at LSTM.

Friday, October 02, 2026

Trump and RFK Jr.’s Gutting of CDC ‘Should Terrify Everyone,’ Advocates Say

“This is not normal,” said the president of the union representing CDC workers. “What we are witnessing is the dismantling of public health infrastructure our country relies on.”



US President Donald Trump speaks while Health and Human Services Secretary Robert F. Kennedy Jr. looks on in the White House in Washington, DC on May 12, 2025.
(Photo by Joyce N. Boghosian/White House/flickr/cc)

Jake Johnson
Sep 28, 2026
COMMON DREAMS


Reporting published over the weekend detailing the “zombified” state of the preeminent public health institution in the US, the Centers for Disease Control and Prevention, sparked deep alarm among advocates and experts, who warned that President Donald Trump’s gutting of the agency leaves the country badly unequipped to handle future emergencies.

“The grim state of affairs at the Trump CDC should terrify everyone,” Brad Woodhouse, president of the advocacy group Protect Our Care, said in a statement on Monday in response to reporting by The New York Times, which shows how Health and Human Services Secretary Robert F. Kennedy Jr. and other administration officials have made the CDC “a skeleton of the powerhouse it was.”

The Times noted that, as of May 2026, the CDC had 30% fewer employees than it did before the Trump administration initiated mass layoffs at the agency and across the federal government last year.

There is also a leadership vacuum at the agency, according to the Times, which reported that “only one of the 11 center directors from March 2025 remains at the agency” and “most of the other centers are being run by acting directors, some of whom were elevated from jobs one or two levels below.” The current CDC director is Dr. Erica Schwartz, who “has made no public statements about the importance of childhood vaccines or corrected misinformation from her boss, Mr. Kennedy,” the Times observed, even as recorded measles cases reach levels not seen in decades.

“Interviews with more than 30 current and former employees reveal the agency is now tightly controlled by Mr. Kennedy and his associates, and its scientists are finding it increasingly difficult to do their jobs effectively,” the newspaper reported.

Dr. Demetre Daskalakis, who headed the CDC’s respiratory disease center before resigning in protest last year, told the Times that the Trump CDC “is not acting like how an agency like that should act.” In his resignation letter, posted to social media in August 2025, Daskalakis warned that “the nation’s health security is at risk and is in the hands of people focusing on ideological self-interest.”

According to the Times, the CDC’s center for emerging and zoonotic diseases, which manages Ebola and hantavirus, “now has nearly 300 fewer employees than in March 2025, and the respiratory disease center has lost nearly 200—about 17% in each case.”

“RFK Jr. has gutted the office that works on dangerous, killer emerging diseases,” US Sen. Chris Murphy (D-Conn.) wrote over the weekend. “Disaster in waiting.”

Woodhouse of Protect Our Care said Monday that “after a catastrophic global pandemic followed by a record-breaking measles crisis, the CDC should be better prepared than ever.”

“Instead, the agency keeps getting caught with its pants down thanks to Donald Trump and RFK Jr.'s self-sabotage and war on science,” said Woodhouse. “Investigations are coming, but resignations should come much sooner.”

The Times reporting coincided with new data from American Federation of Government Employees (AFGE) Local 2883, which represents CDC workers. The union said the CDC has lost over 3,800 employees during Trump’s second term, nearly a third of the agency’s total workforce.

“This is not normal,” said Yolanda Jacobs, president of AFGE Local 2883. “What we are witnessing is the dismantling of public health infrastructure our country relies on.”

“CDC workers have endured eighteen months of chaos and confusion, from detrimental layoffs and RIFs, to being left in a constant state of panic about job security. This turmoil cannot continue,” Jacobs added. “Our workers, who have dedicated their lives to serving the American people, deserve better. Our country deserves an agency that is fully prepared to protect the public’s health within and outside its own doors. Protecting our nation’s public health workers also protects our nation’s public health.”

Thursday, September 17, 2026

 

First-of-its-kind preventative phage therapy provides promising results




Virginia Tech

lab

image: 

(From left) Roger Bataglioli and Hiba Baaziz in the lab.

view more 

Credit: Photo by Felicia Spencer for Virginia Tech.






The mammalian gut microbiome is teeming with a delicate balance of bacteria and the viruses that keep them in check, called bacteriophages, or phages. Each bacterial species usually has its own set of phage partners. 

When bad bacteria enter this ecosystem, there are typically no phages present, allowing them to cause mayhem. By the time the host is sick, it is too late for phages; they’ll simply reach a balance with the bad bacteria.

But what if the phages in the gut could prepare for the orally ingested pathogen and strike it down as it enters the gut, negating the need for a battle?

Associate Professor and Blackwood Junior Faculty Fellow Bryan Hsu and his team recently demonstrated that this prophylactic approach, using an engineered nonpathogenic E. coli bacterium, successfully protected mice from an oral salmonella infection. Their work was published in Nature Microbiology.

The team believes this is a step toward an additional weapon against illnesses. 

“Eventually, in the future, this could be used to treat other diseases,” said Rogerio A. Bataglioli, a postdoctoral fellow in the Department of Biological Sciences and lead author of the study. “It’s not about replacing antibiotics but having one more option on the shelf to fight infections.” 

Bacteriophages, or phages, are viruses of bacteria and do not infect humans or animals. Hsu said phage therapy, the use of phages to treat bacterial infections, is particularly hard to make successful for treating intestinal pathogens. 

“It’s challenging, especially in the gut, because phages and bacteria tend to coexist for long periods of time,” said Hsu, an affiliate with Fralin Life Sciences Institute’s Center for Emerging, Zoonotic, Arthropod-borne Pathogens.  

This coexistence makes establishing the high phage-to-bacteria ratio needed to treat intestinal infections hard to achieve. 

“That’s extremely challenging to achieve in your gut,” Hsu said. “And then once you have a bacterial infection in your gut, a lot of times it’s just not even accessible to phages. It’s already hidden away in the mucosa or cells of your body; it’s not just free-flowing to where the phages would be able to access them.”  

To work around these impediments, the team engineered a nonpathogenic E. coli bacterium to carry a phage that only infects salmonella. This ensures that when the phage is produced, it can specifically target the pathogen.   

Usually, this type of salmonella phage remains dormant in the salmonella bacterial genome, but Hsu’s team made several genetic modifications so that it is carried by E. coli, and, once it is released into the gut, it automatically kills salmonella in a process called lysis. This process rapidly increases the number of phages to fight the bacteria. The researchers coined this new type of phage-bacterial combination a “lytic phage-producing lysogen,” or “lyto-lysogen.”

Salmonella can typically detect phage DNA produced by non-salmonella bacteria and prevent it from replicating. But in this case, the researchers were able to disguise the phage.

“We were able to trick the salmonella bacteria into thinking the phage from E. coli was ‘not foreign’ by adding a salmonella gene into the E. coli genome,” Bataglioli said. “A phage that comes from our E. coli can infect salmonella, can propagate easily in salmonella, lyse it, and then all the phages that are produced from salmonella can just keep replicating.” 

This rapid reproduction eventually leads to the eradication of the infection from the gut. 

“What happens is that this good bacteria, the E. coli, produces all this antipathogen phage, and there is now a protective lining so that when salmonella comes in, just after passing through the stomach and at its weakest point, it meets this high, killer density of phages,” Hsu said.  

The researchers say they targeted salmonella due to its high global disease burden, as it can kill the elderly, children, and those with HIV; it has a high prevalence of antibiotic resistance; and it has been upgraded to a high-priority pathogen by the Centers for Disease Control and Prevention. They believe this work, however, has strong implications for other illnesses. 

“We’re starting off with salmonella, but expanding, obviously, with the correct adaptations to target other diseases; other bacterial pathogens, would be an interesting route to explore,” Bataglioli said. 

“We have a framework in place that shows that we could potentially put other phages in there and target other bacteria,” Hsu said. 

Bataglioli plans to continue his bacteriophage research with the School of Chemical Engineering at the State University of Campinas in São Paulo, Brazil, in the fall.

Funding for this research was provided by the National Institute of General Medical Sciences of the National Institutes of Health. Bataglioli’s funding was supported by the Postdoctoral Fellowship in Drug Delivery from the PhRMA Foundation. 

Other researchers involved in this study include the following: 

  • Hiba Baaziz, Ph.D., lab manager, biological sciences 

  • Hallie Avalos, currently a graduate student at Vanderbilt University Medical Center 

  • Lindsay Smith, undergraduate researcher, College of Science 

  • Zach Baker, Ph.D., current postdoctoral researcher at Colgate-Palmolive 

  • Rita Makhlouf, graduate student, biological sciences

  • David Da Silva Barreira, Ph.D., current postdoctoral researcher at the University of Wisconsin, Madison 

  • Harsimran Kaur, Ph.D., presidential postdoctoral associate in biological sciences 

  • Teresa Southard, associate professor at the Virginia-Maryland College of Veterinary Medicine

Tuesday, September 01, 2026

 

Cancer and virus-free: Bats' longevity genes could hold clues for human health

Bats' longevity genes could hold clues for human health.
Copyright Cleared/Canva


By Marta Iraola Iribarren
Updated

Scientists are studying the mechanisms behind bats' immune systems to uncover what they could teach about human longevity.

Bats are the longest-lived mammals for their size and have the ability to adapt to viruses and boost their defences. Scientists are now trying to see whether humans can learn anything from bats’ ability to resist viruses and even prevent cancer.

A new study published in the journal Nature looked at what these animals can teach about longevity and fighting disease. The findings reveal that the bats' ability to slow ageing and tolerate viruses is genetically linked, suggesting that the same biological 'tricks' protect them from both infections and the decay of old age

“Bats have evolved this incredible fitness capacity, this incredible ability to deal with disease and this incredible ability to be able to prevent cancer,” said Juan Manuel Vazquez, author of the study at the University of California, Berkeley.

“That means that, by understanding how bats have evolved to do all these things that other mammals haven’t, we can find completely new and unexpected ways of dealing with the normal things that cause human diseases.”

For the study, Vazquez travelled to capture, biopsy and release different species of bats. He currently has cell cultures from 259 individuals representing 32 species.

He focused on those in the Myotis genus of bats, known for having some of the most extreme adaptations for longevity and disease resistance among mammals. In this group, the Myotis brandtii (Brandt’s bat) can live up to 42 years.

How bats resist ageing and cancer

By creating high-quality genetic maps for eight different species, the researchers identified the specific biological "tricks" these animals use to survive.

One of the most important findings is that long-lived bats have evolved ways to prevent cancer. For example, the little brown bat (Myotis lucifugus) has an enhanced ability to clear out damaged cells before they can cause harm.

An example of this is a specific immune factor called PKR, as most Myotis species have evolved extra copies of this gene to fight a wider range of viruses.

A different way of fighting viruses

Bats act as zoonotic reservoirs — animals that can carry viruses dangerous to humans without becoming ill themselves. Their ability to do this is a result of a specialised evolutionary strategy known as viral tolerance.

The research found that while most mammals use "resistance" to fight viruses by attempting to eliminate the pathogen, bats have evolved high levels of viral tolerance.

They have developed mechanisms to suppress the damaging inflammation and cellular stress that would normally kill other mammals, which allows the virus to live in their bodies.

For RNA viruses, responsible for human outbreaks such as the COVID-19 pandemic, bats tend to change the number of immune genes they have and evolve extra copies to broaden their defence.

What this means for human disease

Because bats have developed natural solutions to problems like cancer and cellular decay, they provide a roadmap for understanding how these same processes might be managed in humans, the researchers said.

Vazquez noted that bats evolved to live for a long time without getting diseases, which suggests we don't necessarily need to look at diseases of ageing and diseases of infection as completely separate fields.

“We can look at these bats and try to understand how, in the same way you can improve your immune system to fight off viruses, maybe you can improve your immune system so it doesn’t decline in old age,” he noted.

“Or maybe bats can help us find ways to fight off tumors so our immune system doesn’t get tired, and that can also help us deal with other stresses of life and not exhaust our immunity.”